Gene: CECR2

27443
-
CECR2, histone acetyl-lysine reader
protein-coding
22q11.1-q11.21
Ensembl:ENSG00000099954 MIM:607576 Vega:OTTHUMG00000150072 UniprotKB:Q9BXF3
NG_033989.1
SNP Mapped
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.960e-1 (AD)  3.781e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs16982400chr22:17418497 (GRCh38.p7)T>Cnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg07197230chr22:17956641CECR2Promoter3.392e-4Alcohol use disorders26763658
cg01010211chr22:17956453CECR2Promoter9.755e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AASS0.807
ZBTB370.8
CHD70.799
MEIS10.778
TRAF10.776
BAZ2B0.775
CDC14B0.775
ATF70.769
SGK30.763
SNX290.76

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CRH-0.4
LYPD6B-0.394
PNOC-0.394
SULT2B1-0.387
RTP1-0.382
PRTN3-0.38
NPAS1-0.379
LRRC38-0.375
FBLN7-0.371
BHLHA9-0.368

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA"27188386
D001280AtrazineAtrazine results in increased expression of CECR2 mRNA25929836
C006780bisphenol Abisphenol A results in decreased methylation of CECR2 promoter27312807
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of CECR2 mRNA20938992
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of CECR2 mRNA20938992
D017313FenretinideFenretinide results in decreased expression of CECR2 mRNA28973697
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CECR2 mRNA25613284
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of CECR2 mRNA20938992
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA"25510870
D010416PentachlorophenolPentachlorophenol results in decreased expression of CECR2 mRNA23892564
D010634PhenobarbitalPhenobarbital affects the expression of CECR2 mRNA23091169
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA"27188386
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of CECR2 mRNA22714537
C005556propionaldehydepropionaldehyde results in decreased expression of CECR2 mRNA26079696
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CECR2 mRNA26377647
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CECR2 mRNA25613284
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of CECR2 mRNA24935251
D014635Valproic AcidValproic Acid results in decreased expression of CECR2 mRNA28001369

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0006309apoptotic DNA fragmentation-TAS12762840  
GO:0007010cytoskeleton organization-NAS11827465  
GO:0016192vesicle-mediated transport-NAS11827465  
GO:0021915neural tube development-IEA-  
GO:0043044ATP-dependent chromatin remodeling-IDA15640247  
GO:0061640cytoskeleton-dependent cytokinesis-NAS11827465  
GO:0097194execution phase of apoptosis-IDA12762840  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA12762840  
GO:0090537CERF complex-IDA15640247  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal